- Trial phase
- Phase 3
- Time to market
- If the Phase 3 ACTION 3 trial succeeds, a U.S. FDA submission could follow in 2028 or 2029, with potential approval in 2029-2030, assuming standard review timelines.
- Why 3/10
- BMN 820's next hard, dated catalyst is the Phase 3 ACTION 3 pivotal topline data readout, expected in 2028 (more than 12 months away). With no nearer-term binary catalyst and the drug representing a small part of BioMarin's diversified pipeline, the impact score is a 3 per the rubric for a mid-stage drug whose next catalyst is >12 months out.
The next catalyst for BMN 820 is the Phase 3 ACTION 3 topline data readout, expected in 2028. Positive data would validate the FSGS opportunity for BioMarin's U.S. commercialization rights, while a miss would effectively zero out the program's value. In the nearer term, watch for any Dimerix disclosures on trial progress or interim analyses. BMN 820 is a small part of a large, diversified pipeline at BioMarin, so even a binary outcome would likely move BMRN shares by mid-single-digit percentages, not a make-or-break swing.
Price Chart
Executive Summary
BMN 820 (repagermanium, formerly DMX-200) is a first-in-class oral CCR2 inhibitor in Phase 3 development for focal segmental glomerulosclerosis (FSGS), a rare kidney disease with limited treatment options. BioMarin acquired exclusive U.S. commercialization rights through its acquisition of Amicus Therapeutics, which held the license from Australian developer Dimerix. The pivotal Phase 3 ACTION 3 trial (NCT05183646) is fully enrolled with 286 patients and passed a pre-specified interim efficacy analysis, maintaining >90% statistical power. Topline data are expected in 2028. The U.S. addressable patient population is roughly 30,000, but the drug faces a newly approved competitor in Travere's FILSPARI (sparsentan), approved for FSGS in April 2026. BMN 820 is one of several pipeline assets at BioMarin, a large-cap biotech with approved products (VOXZOGO, GALAFOLD) generating over $1 billion in quarterly revenue, so this single drug is not a make-or-break catalyst for the stock.
How It Works
BMN 820 (repagermanium) is an oral small-molecule drug that blocks the CCR2 receptor on immune cells. In focal segmental glomerulosclerosis (FSGS), a rare kidney disease where the kidney's filtering units become scarred, inflammatory signals attract immune cells via the CCR2 pathway, worsening the damage. By blocking CCR2, BMN 820 aims to reduce inflammation and scarring in the kidneys, slowing or halting disease progression. It is designed to be taken alongside a standard blood-pressure medication called an angiotensin II receptor blocker (ARB), and the two drugs work on related pathways that both contribute to kidney injury.
Trial Status
The pivotal Phase 3 ACTION 3 trial (NCT05183646) is fully enrolled with 286 patients across multiple global sites. The trial is a randomized, double-blind, placebo-controlled study evaluating DMX-200 120 mg twice daily versus placebo in FSGS patients on a stable ARB regimen. A pre-specified interim efficacy analysis in March 2024 was successful (non-futile), and an external blinded review confirmed >90% statistical power. The trial has a 104-week double-blind treatment period. Topline pivotal data are expected in 2028. Dimerix operates the trial; BioMarin holds exclusive U.S. commercialization rights.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 ACTION 3 pivotal topline data readout (expected 2028)
- Any Dimerix disclosures on interim analyses or trial progress updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report